1 / 16

Product Development: Initiatives and Experiences

Product Development: Initiatives and Experiences. Rufinamide Paediatric formulation development Inception meeting 26 th Nov 2014. Dr Shital Mahindra Maru Chair and Senior lecturer Dept. Pharmaceutics and Pharmacy Practice. Outline. Scope Drug delivery in Context Technology drivers

blumer
Download Presentation

Product Development: Initiatives and Experiences

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Product Development:Initiatives and Experiences Rufinamide Paediatric formulation development Inception meeting 26th Nov 2014 Dr Shital Mahindra Maru Chair and Senior lecturer Dept. Pharmaceutics and Pharmacy Practice

  2. Outline Scope Drug delivery in Context Technology drivers Core Capabilities at SoP Expertise available at SoP Facilities Collaborative Research, Consultancy and Knowledge transfer Partnerships Postgraduate Studies Conclusion

  3. Scope Formulation, research and development of generic Rufinamide paediatric formulation for use in Lennox-Gastaut syndrome (LGS) Collaboration initiative between academia- industry and regulatory authorities Training of Postgraduate students in various areas of pharmaceutical sciences

  4. Drug Delivery in Context • Drug Delivery is the method or process of administering a pharmaceutical compound to achieve therapeutic benefit • Right amount • Right time • Right tissue Physicaland chemical Properties Physiology of route of administration Formulation and Product Design Dosage Form

  5. Technology Drivers for Paediatric Drug Products Precise, accurate and flexible dosing Palatability Ease of preparation and administration Paediatric Product Drivers Appropriateness for wide range of ages Controlled Release PK and Biopharm Stability Challenging molecules

  6. Core Capabilities-SOP Quality by design

  7. Expertise Department of Pharmaceutics and Pharmacy Practice Dr Nasser Nyambene Nyamweya PhD. Pharm.Sc. University of Maryland, USA, MSc. University of Arkansa USA Dr Lucy Jemtai Tirop B.Pharm (UoN), PhD King’s College London Dr Shital Mahindra Maru B.Pharm (Karnataka University, India), M.Pharm Pharmaceutics (RGHUS, India), PhD Pharmaceutics (UoN), MBA (Uni. Liverpool, UK) Prof. K.A.M Kuria. BSc Pharm. (Sunderland, UK) MSc (UoN), PhD (Katholieke Uni., Belgium)

  8. Expertise .. contd Dept. Pharmacology and Pharmacognosy Dr Margaret Oluka, B.Pharm (UoN), MSc (UoN), PhD(UoN) Dr. Eric Guantai B.Pharm (UoN), MSc (UoN), PhD (UCT, SA) Prof. A.N. Guantai B.Pharm (UoN), MSc (UoN), PhD

  9. Expertise at SoP. Contd. Dept. Pharmaceutical Chemistry 1. Dr John Ogeto BPharm, MSc Pharmaceutical Sciences (Bradford, Uk) 2. Dr B. Amugune B.Pharm (UoN), MPharm (UoN), PhD (UoN) 3. Dr K. Abuga B.Pharm (UoN), MPharm (Katholieke Uni, Belgium), PhD (UoN)

  10. Facilities Stability Chamber (KBF720, Germany) HPLC (Shimadzu, Japan) GC-MS (Shimadzu, Japan) UV-VIS Spectrophotometer (Prestige-21) Infra- red (IR) Spectrophotometer Dissolution apparatus (Erweka DT6, Germany) Disintegration tester (Erweka V-110 HZ 60, Germany) Friability tester (Erweka, TA3 HZ 60, Germany) Automatic Single punch Tablet Press (Erweka, EP-1, Germany) Electronic Tablet Hardness Tester (Schleuniger-2E, Germany) Multipurpose motor drive with attachments (Erweka, AR 400, Germany

  11. Contract Research Work Drug Analysis Research Unit (DARU): Quality control, Quality Assurance and Analytical method development, Process Analytical Technology (PAT) Pharmaceutical product Development Unit: Formulation and process technology development, Quality by design (QbD) concepts for product development Pharmacological studies : animal models, Clinical trials and Bioequivalence studies Pharmacovigilence studies: Post market surveillance studies Pharmcoepidemiology studies

  12. Collaborative Research, Consultancy, Knowledge Transfer Partnerships We look forward for more work in the following areas • Continuous granulation • Continuous tableting • Solubility and Dissolution Improvements • Modified Release systems • Paediatric and geriatric formulation development • Taste making • Trans dermal and muco-adhesive films • Coating technology • Polymer science • PAT (In Line measurements)

  13. Collaborative work .. Contd Industry sponsored Masters and PhD studentships Collaborate to generate new Intellectual Property (IP) - with option to exploit new IP through Joint Venture

  14. Postgraduate Studiesand Placement Schemes • Opportunities for Masters and PhD students to do research in various areas like • M.Pharm Industrial Pharmacy student: Pre formulation studies on Rufinamide and excipients used for solid oral and liquid oral dosage forms • M.Pharm Pharmaceutical Analysis on analytical method development and validation for Rufinamide • PhD studies on how to improve solubility and permeability of Rufinamide and use novel drug delivery system like solid dispersion or nano particulate system • PhD Pharmacology on Clinical trials and bioequivalence studies of prepared formulation

  15. Concluding Remarks Strong drivers for application of formulation development of Rufinamide for Paediatric patients Necessity for rapid and affordable access to Rufinamide paediatric formulation in East Africa increases the emphasis for adoption of flexible dosing platform technologies (age appropriate dosing) Potential to develop and scale up pharmaceutical production of generic Rufinamide paediatric formulation locally

  16. THANK YOU

More Related